The MedCity INVEST PharmaTech virtual conference scheduled for Tuesday, July 26, will cast a spotlight on the many ways pharma companies are using digital health tech to support many aspects of their work. Among these applications are AI to identify targets for drug development, the future of digital medicines, the impact of Covid-19 on clinical trials, and more.
Here’s a preview of what the virtual conference has to offer. You can access the full agenda here.
The future of digital medicines (Sponsored by Emergn)
The landscape of digital medicines holds great promise though so far has been a story of failure. Still, a new generation of companies is aiming to transform the digital therapeutics market. Learn from experts in the field of pharma, digital health and commercialization.
Moderator: Carrie Northcott, senior director, project lead digital medicine and translational imaging, Pfizer
Speakers:
- Lana Ghanem, managing director, Hikma Ventures
- Pierre Leurent, president, digital health, Aptar Pharma
- Mario Moreira, principal consultant, Emergn
- Abhishek Shah, co-founder and CEO, Wellthy Therapeutics
Pharma + Digital: Here’s how to make it a match made in heaven
Saying that the culture of pharma and health tech worlds are different is a broad understatement. But they each have elements that the other requires. What are the strategies for better alignment and partnerships.
Moderator: Naomi Fried, CEO and founder, Pharmstars
Speakers:
- Jessica Federer, partner, Boston Millennia Partners
- Charles Fisher, founder and CEO, Unlearn.AI
- Joel Krikston, managing director venture investments and head of strategic innovation alliances, Merck Global Health Innovation Fund
- Jim Parshall, senior director – connected health and devices external innovation, Eli Lilly and Company
The state of AI in drug discovery
Artificial intelligence in healthcare is finally emerging from being overhyped to showing some practical applications. If it succeeds in the realms of drug discovery, that will be a monumental achievement helping both to speed up and lower the cost for drug development. Learn from experts about where we are in leveraging AI effectively for drug discovery.
Moderator: Frank Vinluan, senior biopharma reporter, MedCity News
Speakers:
- Nathan Benaich, founder and general partner, Air Street Capital
- Chris Gibson, co-founder and CEO, Recursion
- Najat Khan, chief data science officer, global head, strategy and operations, Janssen Pharmaceuticals
- Richard Law, chief business officer, Exscientia
The day’s panel discussions will culminate in the Pitch Perfect contest featuring five companies seeking to re-invent clinical trials with differing approaches. Judges for the competition include:
- Cris De Luca, partner, digital, Sanofi Ventures
- Jessica Federer, partner, Boston Millennia Partners
- Joel Krikston, managing director venture investments and head of strategic innovation alliances, Merck Global Health Innovation Fund
- Maxim Owen, venture partner, Wavemaker Three-Sixty Health
To check out the competing startups, click here.
Photo: Who_I_am, Getty Images
